4D Molecular Therapeutics, Inc. (FDMT) stock forecast and price target
Price $12.23 · data as of November 13, 2026
12-month price target
Average target$28.09
Upside / downside+129.7%
Analysts11
ConsensusStrong buy
Low $18.00Average $28.09High $37.00
Gold marker: average target · white marker: today’s price ($12.23)
Analyst ratings
Strong buy 2Buy 9Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-4.16 | −72.0% | $13M |
| Next fiscal year ends December 31, 2027 | $-4.19 | −0.7% | $17M |
| Next quarter ends December 31, 2026 | $-1.04 | −341.6% | $3M |
| Quarter after ends March 31, 2027 | $-1.12 | −11.4% | $2M |
Consensus of the analysts covering 4D Molecular Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the 4D Molecular Therapeutics stock price target?
The average 12-month target from 11 analysts is $28.09, 129.7% above the current price of $12.23 Targets range from $18.00 to $37.00.
Is 4D Molecular Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 9 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is 4D Molecular Therapeutics expected to earn?
Analysts expect EPS of $-4.16 for the fiscal year ending December 31, 2026 and $-4.19 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.